# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and raises the price target from $143 to $151.
Last week's top performers included Carvana, Pinterest, Moderna and JD.Com.
Canaccord Genuity analyst Bill Maughan maintains Moderna (NASDAQ:MRNA) with a Hold and raises the price target from $91 to $...
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $125 to $135.
Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $142 to ...